This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.
BETHESDA, Maryland-ThreeNational Institutes of Health (NIH)units will provide $12 million over 5years to support seven new centersparticipating in the National CancerInstitute's Transdisciplinary TobaccoUse Research Center (TTURC) program.NCI will provide $7 million, withthe rest coming from the National Instituteon Drug Abuse and the NationalInstitute on Alcohol Abuse andAlcoholism.NCI began its collaborative tobaccoresearch initiative in 1999 with theawarding of grants to seven institutionsto establish centers. The newround of funding will support a spectrumof topics important to understandingtobacco-related diseases,their control, and psychosocial factorsthat influence smoking.The locations of the new centersand the principal investigators are:Brown University and Miriam Hospital,Raymond Niaura, PhD; University of Wisconsin, Timothy B.Baker, PhD; Roswell Park Cancer Institute,K. Michael Cummings, PhD;University of Minnesota, Dorothy K.Hatsukami, PhD; University of SouthernCalifornia, C. Anderson Johnson,PhD; University of Pennsylvania,Caryn E. Lerman, PhD; and Yale University,Stephanie S. O'Malley, PhD.In announcing the new grants, NCIsaid that work at the original sevencenters had yielded important scientificfindings. Among the researchfindings cited by the institute:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.